TY - JOUR
T1 - Vulvar Cancer, Version 3.2024
AU - Abu-Rustum, Nadeem R.
AU - Yashar, Catheryn M.
AU - Arend, Rebecca
AU - Barber, Emma
AU - Bradley, Kristin
AU - Brooks, Rebecca
AU - Campos, Susana M.
AU - Chino, Junzo
AU - Chon, Hye Sook
AU - Crispens, Marta Ann
AU - Damast, Shari
AU - Fisher, Christine M.
AU - Frederick, Peter
AU - Gaffney, David K.
AU - Gaillard, Stephanie
AU - Giuntoli, Robert
AU - Glaser, Scott
AU - Holmes, Jordan
AU - Howitt, Brooke E.
AU - Kendra, Kari
AU - Lea, Jayanthi
AU - Lee, Nita
AU - Mantia-Smaldone, Gina
AU - Mariani, Andrea
AU - Mutch, David
AU - Nagel, Christa
AU - Nekhlyudov, Larissa
AU - Podoll, Mirna
AU - Rodabaugh, Kerry
AU - Salani, Ritu
AU - Schorge, John
AU - Siedel, Jean
AU - Sisodia, Rachel
AU - Soliman, Pamela
AU - Ueda, Stefanie
AU - Urban, Renata
AU - Wethington, Stephanie L.
AU - Wyse, Emily
AU - Zanotti, Kristine
AU - McMillian, Nicole
AU - Espinosa, Sara
N1 - Publisher Copyright:
© 2024, National Comprehensive Cancer Network® (NCCN®). All rights reserved.
PY - 2024/3
Y1 - 2024/3
N2 - Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. Vulvar cancer accounts for 5% to 8% of gynecologic malignancies. Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency. Most vulvar neoplasias are diagnosed at early stages. Rarer histologies exist and include melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous carcinoma, basal cell carcinoma, and sarcoma. This manuscript discusses recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for treatments, surveillance, systemic therapy options, and gynecologic survivorship.
AB - Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. Vulvar cancer accounts for 5% to 8% of gynecologic malignancies. Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency. Most vulvar neoplasias are diagnosed at early stages. Rarer histologies exist and include melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous carcinoma, basal cell carcinoma, and sarcoma. This manuscript discusses recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for treatments, surveillance, systemic therapy options, and gynecologic survivorship.
UR - http://www.scopus.com/inward/record.url?scp=85188760693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85188760693&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.0013
DO - 10.6004/jnccn.2024.0013
M3 - Article
C2 - 38503056
AN - SCOPUS:85188760693
SN - 1540-1405
VL - 22
SP - 117
EP - 135
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
ER -
